FONDATION ARC POUR LA RECHERCHE SUR LE CANCER

Their core work

Fondation ARC is one of France's leading private cancer research funding organizations, headquartered in Villejuif near the major Gustave Roussy cancer campus. In the H2020 context, they act as a national funding agency that co-finances transnational cancer research through ERA-NET mechanisms, aligning French cancer research priorities with European programmes. They also contribute to large-scale clinical research, notably in personalized breast cancer screening. Their primary function is channeling philanthropic funding into cancer prevention, treatment research, and coordinating national research agendas with pan-European efforts.

What they specialise in

How they've shifted over time

With only three projects and no early-period keywords recorded, the evolution is best read through project timelines. The foundation began with TRANSCAN-2 (2015), a first-generation effort to align national cancer research programmes, then joined MyPeBS (2018) in a more applied, clinical direction — personalized breast cancer screening using genetics. By 2021, they continued the coordination role through TRANSCAN-3, suggesting a deepening commitment to the funding-body and programme-alignment function rather than a pivot. The addition of MyPeBS signals a growing interest in precision medicine applications alongside their core coordination work.

Fondation ARC is consolidating its role as a European cancer research funding coordinator while selectively engaging in precision medicine clinical studies, suggesting future interest in risk-stratified and genetics-driven cancer prevention.

How they like to work

Fondation ARC exclusively participates as a partner, never as a coordinator — consistent with their identity as a funding body rather than a research-performing institution. Their 70 unique partners across 24 countries from just 3 projects reflects the very large consortia typical of ERA-NET mechanisms, where multiple national funding agencies pool resources. This means they are well-connected across Europe's cancer research funding landscape but their partnerships are structural (funding agency networks) rather than research-driven.

Despite only three projects, Fondation ARC has worked with 70 partners across 24 countries, reflecting the broad, multi-national nature of ERA-NET funding networks. Their reach spans most of the EU and associated countries, anchored by the cancer research funding community.

What sets them apart

Fondation ARC occupies a distinctive niche as a private philanthropic foundation acting within the ERA-NET funding coordination ecosystem — most participants in these networks are government agencies or public research councils. Their involvement signals that French private cancer research funding is directly wired into European programme alignment. For consortium builders, they offer access to French cancer research funding streams and credibility as a nationally recognized cancer charity with deep roots in the French research community.

Highlights from their portfolio

• TRANSCAN-3
  Largest funding (€404,589) and a continuation ERA-NET sustaining transnational cancer research coordination through 2027, indicating long-term European commitment.
• MyPeBS
  A major international randomized clinical study on personalized breast cancer screening running until 2027, representing Fondation ARC's direct involvement in precision medicine research beyond its funding-body role.